Skip to main content
. 2021 May 19;6(12):4640–4653. doi: 10.1016/j.bioactmat.2021.05.002

Table 2.

Baseline characteristics of interventions included in the analysis.

Interventions n = 328 Percentage %
Mastectomy Prophylactic 61 18.6%
Therapeutic 267 81.4%
Mastectomy NSM 229 69.8%
NSM-modified “T-inverted” 17 5.2%
SRM - Nipple Sparing 10 3.0%
SRM- No Nipple Sparing 7 2.1%
SSM 65 19.8%
Previous Surgery 1 = Wide Excision Unilateral 34 10.4%
2 = Wide Excision Contralateral 5 1.5%
4 = QUART Unilateral 34 10.4%
5 = QUART Contralateral 7 2.1%
6 = Breast Augmentation 7 2.1%
7 = Contralateral Mastectomy 22 6.7%
8 = None 219 66.8%
Axilla SNB Final 102 31.1%
SNB Intraoperative Negative 77 23.5%
SNB + Axillary Dissection 22 6.7%
SNB + Axillary Dissection Delayed 15 4.6%
Axillary Dissection 37 11.3%
No 75 22.9%
Cutting Linear 59 18.0%
Periareolar 21 6.4%
S in External Quadrants 200 61.0%
Inframammary Fold 10 3.0%
Inverted T 36 11.0%
Vertical 2 0.6%
Radiotherapy No adjuvant 278 85.0%
Yes adjuvant 49 15.0%
Chemotherapy Adjuvant 93 28.4%
Neo-adjuvant 30 9.1%
No 205 62.5%
Hormone Therapy No 138 42.2
Yes 189 57.8
Trastuzumab No 277 84.7
Yes 50 15.3
Device Prosthesis (DTI) 192 58.5
Expander (TE) 136 41.5
pT T0 79 24.1
Tis 44 13.4
T1 156 47.6
T2 47 14.3
T3 2 0.6
pN N0-X 251 76.4
N1 52 15.9
N2 13 4.0
N3 12 3.7
ER 30 9.1
+ 214 65.2
Not performed 84 25.6
PgR 52 15.9
+ 192 58.5
Not performed 84 25.6
Ki67 <20% 79 24.1
>20% 130 36.9
Not performed 119 36.3
Her 2 Amplified 51 15.5
Lymph-nodes invasion Absent 145 44.2
Present 56 17.1
Missing 127 38.7